Education
About Us
Working with TipRanks
Follow Us
Larimar Therapeutics, Inc. (LRMR)
NASDAQ:LRMR
LRMR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.52 - $11.20
Previous CloseN/A
Volume147.46K
Average Volume (3M)578.30K
Market Cap
$169.09M
Enterprise Value$219.59M
Total Cash (Recent Filing)$49.33M
Total Debt (Recent Filing)$20.64M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Mar 12, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding63,806,630
10 Day Avg. Volume512,511
30 Day Avg. Volume578,296
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.30
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-706.06
Enterprise Value/Ebitda-2.99
Forecast
1Y Price Target
$20.33Price Target Upside655.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Larimar Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe partial clinical hold has been lifted, allowing LRMR to transition OLE patients to a 50mg dose, making future readouts more informative.
Regulatory FlexibilityThe FDA's decision to grant Priority Review to vatiquinone, despite it missing its Phase 3 endpoints, highlights regulatory flexibility and unmet need in Friedreich’s ataxia, which positively influences Larimar’s prospects.
Bears Say
Safety ConcernsShares have sold off after the company reported serious adverse events at the last update.
---
Ownership Overview
35.24% Insiders
8.07% Mutual Funds
0.34% Other Institutional Investors
49.43% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LRMR FAQ
What was Larimar Therapeutics, Inc.’s price range in the past 12 months?
Larimar Therapeutics, Inc. lowest stock price was $2.52 and its highest was $11.20 in the past 12 months.
What is Larimar Therapeutics, Inc.’s market cap?
Larimar Therapeutics, Inc.’s market cap is $169.09M.
When is Larimar Therapeutics, Inc.’s upcoming earnings report date?
Larimar Therapeutics, Inc.’s upcoming earnings report date is Mar 12, 2025 which is yesterday.
How were Larimar Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Larimar Therapeutics, Inc. overvalued?
According to Wall Street analysts Larimar Therapeutics, Inc.’s price is currently Undervalued.
Does Larimar Therapeutics, Inc. pay dividends?
Larimar Therapeutics, Inc. does not currently pay dividends.
What is Larimar Therapeutics, Inc.’s EPS estimate?
Larimar Therapeutics, Inc.’s EPS estimate is -0.32.
How many shares outstanding does Larimar Therapeutics, Inc. have?
Larimar Therapeutics, Inc. has 63,806,630 shares outstanding.
What happened to Larimar Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Larimar Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LRMR
---
Larimar Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.33 (655.76% Upside)
$20.33 (655.76% Upside)
Blogger Sentiment
Bullish
LRMR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 581.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.29%
12-Months-Change
Fundamentals
Return on Equity
-44.50%
Trailing 12-Months
Asset Growth
110.69%
Trailing 12-Months
Company Description
Larimar Therapeutics, Inc.
Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA.
---
LRMR Stock 12 Month Forecast
Average Price Target
$20.33
▲(655.76% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Sarepta Therapeutics
―
Ultragenyx Pharmaceutical
―
Voyager Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering LRMR
1 Year
1 Year Success Rate
3/6 ratings generated profit
1 Year Average Return
+35.68%
reiterated a buy rating 3 months ago
Copying Yatin Suneja's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +35.68% per trade.
---